PHARMACOKINETICS OF CEFODIZIME IN ELDERLY PATIENTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT

被引:6
|
作者
VEYSSIER, P
DEVILLERS, A
DOMART, Y
FOURTILLAN, JB
BRYSKIER, A
PROCYK, T
机构
[1] CHU POITIERS,F-86021 POITIERS,FRANCE
[2] CTR HOSP V DUPOUY,ARGENTEUIL,FRANCE
关键词
D O I
10.1093/jac/26.suppl_C.77
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In young adults, the elimination half-life of cefodizime is 3.5—4 h. A pharmacokinetic study was performed in eight patients, aged 63 to 85 years, divided into two groups with the following creatinine clearances (group I: ≥ 50 ml/min and group II: < 30 ml/min). Cefodizime was administered as a 1.0-g iv bolus. In group I, pharmacokinetic parameters did not differ from those observed in young healthy volunteers in a previous study. In group II, the half-life was increased (3.42–7.41 h). There is a linear correlation between the creatinine clearance and total clearance. The daily dose given needs to be based not on the age of the patient but on the degree of renal impairment. In elderly patients with severe renal impairment, the daily dose should be reduced if the creatinine clearance falls below 30 ml/min. © 1990 The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:77 / 81
页数:5
相关论文
共 50 条
  • [21] Single dose pharmacokinetics of α-dihydroergocryptine in patients with moderate to severe renal insufficiency
    de Mey, C
    Sulowicz, W
    Stompór, T
    Ezan, E
    Retzow, A
    Althaus, M
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2003, 53 (11): : 769 - 773
  • [22] EFFECT OF MODERATE OR SEVERE HEPATIC IMPAIRMENT ON CLARITHROMYCIN PHARMACOKINETICS
    CHU, SY
    GRANNEMAN, GR
    PICHOTTA, PJ
    DECOURT, JP
    GIRAULT, J
    FOURTILLAN, JB
    JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (05): : 480 - 485
  • [23] EFFICACY AND SAFETY OF CILAZAPRIL IN HYPERTENSIVE PATIENTS WITH MODERATE TO SEVERE RENAL IMPAIRMENT
    CARLSEN, JE
    HANSEN, FM
    JENSEN, HA
    AMERICAN JOURNAL OF MEDICINE, 1989, 87 (6B): : S79 - S82
  • [24] PHARMACOKINETICS AND SAFETY OF DORZOLAMIDE (MK-507) IN PATIENTS WITH MODERATE RENAL IMPAIRMENT
    CONNOR, J
    KEILANI, T
    SEGAL, R
    WINCHELL, G
    TANAKA, W
    SWITHENBANK, R
    LEVINE, B
    BATLLE, D
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1995, 36 (04) : S738 - S738
  • [25] Evaluation of microalbuminuria as an indicator of renal impairment in patients with moderate to severe psoriasis
    Ladeira de Oliveira, F.
    Bressan, A.
    Azulay-Abulafia, L.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 79 - 80
  • [26] Population Pharmacokinetics and Therapeutic Efficacy of Febuxostat in Patients with Severe Renal Impairment
    Hira, Daiki
    Chisaki, Yugo
    Noda, Satoshi
    Araki, Hisazumi
    Uzu, Takashi
    Maegawa, Hiroshi
    Yano, Yoshitaka
    Morita, Shin-ya
    Terada, Tomohiro
    PHARMACOLOGY, 2015, 96 (1-2) : 90 - 98
  • [27] PHARMACOKINETICS OF THE PROTON PUMP INHIBITOR PANTOPRAZOLE IN PATIENTS WITH SEVERE RENAL IMPAIRMENT
    LINS, RL
    DECLERCQ, I
    HARTMANN, M
    HUBER, R
    BLIESATH, H
    LUHMANN, R
    WURST, W
    GASTROENTEROLOGY, 1994, 106 (04) : A126 - A126
  • [28] Pharmacokinetics of single-dose morinidazole in patients with severe renal impairment
    Zhang, Hao
    Huang, Lu
    Huang, Yuan-yuan
    Yi, Bin
    Pei, Qi
    Tan, Hong-yi
    Huang, Jie
    Liu, Ji-shi
    Yuan, Hong
    Yang, Guo-ping
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2014, 52 (02) : 159 - 165
  • [29] Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment
    Vidya Perera
    Grigor Abelian
    Danshi Li
    Zhaoqing Wang
    Liping Zhang
    Susan Lubin
    Akintunde Bello
    Bindu Murthy
    Clinical Pharmacokinetics, 2022, 61 : 1405 - 1416
  • [30] Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment
    Perera, Vidya
    Abelian, Grigor
    Li, Danshi
    Wang, Zhaoqing
    Zhang, Liping
    Lubin, Susan
    Bello, Akintunde
    Murthy, Bindu
    CLINICAL PHARMACOKINETICS, 2022, 61 (10) : 1405 - 1416